^
    Back
    Association details:
    Biomarker:ROS1 positive
    Cancer:Solid Tumor
    Drug:unecritinib (TQ-B3101) (ALK inhibitor, ROS1 inhibitor, c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

    Excerpt:
    ...5.Subjects in the screening period should provide a written report of ROS1 positive, or tumor histological specimens obtained at the time of diagnosis/post before enrollment are sent to the central laboratory to confirm ROS1 positive....
    Trial ID:
    NCT03972189
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101.

    Published date:
    05/28/2020
    Excerpt:
    Tumor response was evaluated in 24 pts with ALK+/ROS1+/MET amplification….TQ-B3101 was well tolerated and showed preliminary antitumor activity in ALK+, ROS1+ and MET amplification pts. 
    DOI:
    10.1200/JCO.2020.38.15_suppl.e21705
    Trial ID:
    NCT03019276